Over-expression of uPA increases risk of liver injury in pAAV-HBV transfected mice

World Journal of Gastroenterology

Volumn 18, Issue 16, 2012, Pages 1892-1902

  Zhou, Xiao Jun ^a   Sun, Shi Hui ^a   Wang, Peng ^b   Yu, Hong ^a   Hu, Jing Ya ^a   Shang, Shi Cheng ^b   Zhou, Yu Sen ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Beijing Experimental Animal Center   (China)

Author keywords

Albumin promoter; Hydrodynamic transfection; liver injury; Tet on system; Urokinase type plasminogen activator

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; GAMMA INTERFERON; HEPATITIS B ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DNA SEQUENCE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER INJURY; LIVER REGENERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; VIRUS REPLICATION;

EID: 84860487218     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i16.1892     Document Type: Article

References (37)

1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60
2. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96: 4091-4095
3. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004; 25: 450-455
4. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9: 714-724
5. Ossowski L, Clunie G, Masucci MT, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1991; 115: 1107-1112
6. Lund AH, Turner G, Trubetskoy A, Verhoeven E, Wientjens E, Hulsman D, Russell R, DePinho RA, Lenz J, van Lohuizen M. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet 2002; 32: 160-165
7. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91: 869-874
8. Mustjoki S, Sidenius N, Sier CF, Blasi F, Elonen E, Alitalo R, Vaheri A. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000; 60: 7126-7132
9. Dobrovolsky VN, Heflich RH. On the use of the T-REx tetracycline- inducible gene expression system in vivo. Biotechnol Bioeng 2007; 98: 719-723
10. Stieger K, Belbellaa B, Le Guiner C, Moullier P, Rolling F. In vivo gene regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev 2009; 61: 527-541
11. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lübbert H, Bujard H. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 1996; 93: 10933-10938
12. Lamartina S, Roscilli G, Rinaudo CD, Sporeno E, Silvi L, Hillen W, Bujard H, Cortese R, Ciliberto G, Toniatti C. Stringent control of gene expression in vivo by using novel doxycycline- dependent trans-activators. Hum Gene Ther 2002; 13: 199-210
13. Huang LR, Wu HL, Chen PJ, Chen DS. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA 2006; 103: 17862-17867
14. Bidgoli SA, Zavarhei MD, Mohagheghil MH, Yazdanmehr B, Daryani NE, Ardalan FA. Differential expression of uPA in chronic hepatitis B and C, liver cirrhosis and hepatocellular carcinoma: comparison with normal liver tissues and liver metastatic tumors. Int J Cancer Res 2007; 3: 25-32
15. Zhou H, Wu X, Lu X, Chen G, Ye X, Huang J. Evaluation of plasma urokinase-type plasminogen activator and urokinase- type plasminogen-activator receptor in patients with acute and chronic hepatitis B. Thromb Res 2009; 123: 537-542
16. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL, Kneteman NM. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933
17. Barth H, Robinet E, Liang TJ, Baumert TF. Mouse models for the study of HCV infection and virus-host interactions. J Hepatol 2008; 49: 134-142
18. Ernst E, Schönig K, Bugert JJ, Bläker H, Pfaff E, Stremmel W, Encke J. Generation of inducible hepatitis C virus transgenic mouse lines. J Med Virol 2007; 79: 1103-1112
19. Katoh M, Tateno C, Yoshizato K, Yokoi T. Chimeric mice with humanized liver. Toxicology 2008; 246: 9-17
20. Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 1991; 66: 245-256
21. Suemizu H, Hasegawa M, Kawai K, Taniguchi K, Monnai M, Wakui M, Suematsu M, Ito M, Peltz G, Nakamura M. Establishment of a humanized model of liver using NOD/Shiscid IL2Rgnull mice. Biochem Biophys Res Commun 2008; 377: 248-252
22. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551
23. Gossen M, Freundlieb S, Bender G, Müller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769
24. Albanese C, Hulit J, Sakamaki T, Pestell RG. Recent advances in inducible expression in transgenic mice. Semin Cell Dev Biol 2002; 13: 129-141
25. Bockamp E, Maringer M, Spangenberg C, Fees S, Fraser S, Eshkind L, Oesch F, Zabel B. Of mice and models: improved animal models for biomedical research. Physiol Genomics 2002; 11: 115-132
26. van der Weyden L, Adams DJ, Bradley A. Tools for targeted manipulation of the mouse genome. Physiol Genomics 2002; 11: 133-164
27. Hirano T, Kaneko S, Kaneda Y, Saito I, Tamaoki T, Furuyama J, Tamaoki T, Kobayashi K, Ueki T, Fujimoto J. HVJliposome- mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice. Gene Ther 2001; 8: 80-83
28. Shi Y, Son HJ, Shahan K, Rodriguez M, Costantini F, Derman E. Silent genes in the mouse major urinary protein gene family. Proc Natl Acad Sci USA 1989; 86: 4584-4588
29. Zhao X, Araki K, Miyazaki J, Yamamura K. Developmental and liver-specific expression directed by the serum amyloid P component promoter in transgenic mice. J Biochem 1992; 111: 736-738
30. Thome J, Gewirtz JC, Sakai N, Zachariou V, Retz-Junginger P, Retz W, Duman RS, Rösler M. Polymorphisms of the human apolipoprotein E promoter and bleomycin hydrolase gene: risk factors for Alzheimer's dementia? Neurosci Lett 1999; 274: 37-40
31. Pinkert CA, Ornitz DM, Brinster RL, Palmiter RD. An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes Dev 1987; 1: 268-276
32. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266
33. Takikawa Y, Suzuki K. Is AFP a new reliable marker of liver regeneration in acute hepatic failure? J Gastroenterol 2002; 37: 681-682
34. al-Wabel A, al-Janadi M, Raziuddin S. Cytokine profile of viral and autoimmune chronic active hepatitis. J Allergy Clin Immunol 1993; 92: 902-908
35. Geneva-Popova M, Murdjeva M. Study on proinflammatory cytokines (IL-1 beta, IL-6, TNF-alpha) and IL-2 in patients with acute hepatitis B. Folia Med (Plovdiv) 1999; 41: 78-81
36. Hsu HY, Chang MH, Ni YH, Lee PI. Cytokine release of peripheral blood mononuclear cells in children with chronic hepatitis B virus infection. J Pediatr Gastroenterol Nutr 1999; 29: 540-545
37. Diao J, Garces R, Richardson CD. X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev 2001; 12: 189-205